, Données d'hospitalisation

, Les patients les plus graves selon le score de gravité (modérée / sévère) ne sont pas plus souvent, ni plus longtemps hospitalisés que les autres. Ce score ne tient compte que des atteintes d'organes et non de la survenue d'événement aigus transitoires comme les CVO, les STA ou les infections

, En revanche il existe une corrélation positive entre le nombre de jours d'hospitalisations et le nombre d'organes atteints, ce qui n'est pas retrouvé avec le nombre de séjours. Ces résultats sont à rapprocher de ceux retrouvés chez les patients de plus de 45 ans, qui sont aussi ceux qui présentent le plus grand nombre d'organes atteints, vol.14

, Toutefois il ne prend pas en compte des données dynamiques telles que le nombre d'épisode de STA ou de CVO, qui sont identifiés aujourd'hui dans la littérature comme facteurs de risque de mortalité.(63) A titre d'exemple, Tweel et al. ont proposé en 2010 un score validé en pédiatrie permettant de grader la sévérité en trois niveaux : A, B et C. Ce score prend en compte : ONA, AVC ou vasculopathie cérébrale, Le score de gravité utilisé dans cette étude est un score composite qui prend en compte cinq atteintes d'organe. Il a été utilisé par d'autres auteurs

F. B. Piel, A. P. Patil, R. E. Howes, O. A. Nyangiri, P. W. Gething et al., Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical modelbased map and population estimates. The Lancet, vol.381, pp.142-51, 2013.

, Haute Autorité de Santé -Dépistage néonatal de la drépanocytose en France, 2019.

, Filière de santé MCGRE -Maladies du Globule Rouge et de l'Erythropoïèse, 2019.

S. A. Zimmerman, E. E. O'branski, W. F. Rosse, and R. E. Ware, Hemoglobin S/O(Arab): thirteen new cases and review of the literature, Am J Hematol, vol.60, issue.4, pp.279-84, 1999.

H. Elmariah, M. E. Garrett, D. Castro, L. M. Jonassaint, J. C. Ataga et al., Factors associated with survival in a contemporary adult sickle cell disease cohort, Am J Hematol, vol.89, issue.5, pp.530-535, 2014.

K. Gardner, A. Douiri, E. Drasar, M. Allman, A. Mwirigi et al., Survival in adults with sickle cell disease in a high-income setting, Blood, vol.128, issue.10, pp.1436-1444, 201608.

. Crise-migratoire-en-europe, Wikipédia [Internet, 2019.

, Comprendre la crise des migrants en Europe en cartes, graphiques et vidéos, 2015.

J. Flint, R. M. Harding, A. J. Boyce, and J. B. Clegg, The population genetics of the haemoglobinopathies, Baillieres Clin Haematol, vol.11, issue.1, pp.1-51, 1998.

R. L. Nagel and A. F. Fleming, Genetic epidemiology of the beta s gene, Baillieres Clin Haematol, vol.5, issue.2, pp.331-65, 1992.

F. B. Piel, A. P. Patil, R. E. Howes, O. A. Nyangiri, P. W. Gething et al., Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis, Nat Commun, vol.1, p.104, 2010.

F. B. Piel and D. J. Weatherall, The ?-thalassemias, N Engl J Med, vol.371, pp.1908-1924, 1920.

F. Bernaudin, S. Verlhac, S. Chevret, M. Torres, L. Coic et al., G6PD deficiency, absence of ?-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia, Blood, vol.112, issue.10, pp.4314-4321, 2008.

F. Bernaudin, C. Arnaud, A. Kamdem, I. Hau, F. Lelong et al., Biological impact of ? genes, ? haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea, Blood Adv, vol.2, issue.6, pp.626-663, 2018.

K. Ohene-frempong, S. J. Weiner, L. A. Sleeper, S. T. Miller, S. Embury et al., Cerebrovascular accidents in sickle cell disease: rates and risk factors, Blood, vol.91, issue.1, pp.288-94, 1998.

O. S. Olatunya, D. M. Albuquerque, A. Adekile, and F. F. Costa, Influence of alpha thalassemia on clinical and laboratory parameters among nigerian children with sickle cell anemia, J Clin Lab Anal, vol.33, issue.2, p.22656, 2019.

M. Kayle, S. L. Docherty, R. Sloane, P. Tanabe, G. Maslow et al., Transition to adult care in sickle cell disease: A longitudinal study of clinical characteristics and disease severity. Pediatr Blood Cancer, vol.66, p.27463, 2019.

O. Castro, D. J. Brambilla, B. Thorington, C. A. Reindorf, R. B. Scott et al., The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease, Blood, vol.84, issue.2, pp.643-652, 1994.

E. P. Vichinsky, L. D. Neumayr, A. N. Earles, R. Williams, E. T. Lennette et al., Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group, N Engl J Med, vol.342, issue.25, pp.1855-65, 2000.

V. Allareddy, A. Roy, M. K. Lee, R. P. Nalliah, S. Rampa et al., Outcomes of Acute Chest Syndrome in Adult Patients with Sickle Cell Disease: Predictors of Mortality, PLoS ONE, vol.9, issue.4, 2014.

D. R. Powars, L. S. Chan, A. Hiti, E. Ramicone, and C. Johnson, Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore), vol.84, pp.363-76, 2005.

X. J. Duan, S. Lanzkron, M. O. Linz, C. Ewing, J. Wang et al., Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy, Am J Ophthalmol, vol.197, pp.105-118, 2019.

G. Arduini, T. De-marqui, and A. B. , Prevalence and Characteristics of Priapism in Sickle Cell Disease, Hemoglobin, vol.42, issue.2, pp.73-80, 2018.

O. Adesina, A. Brunson, T. Keegan, and T. Wun, Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California, vol.1, pp.1287-95, 2017.

M. Mukisi-mukaza, A. Elbaz, Y. Samuel-leborgne, L. Kéclard, L. Turdu-chicot et al., Prevalence, clinical features, and risk factors of osteonecrosis of the femoral head among adults with sickle cell disease, Orthopedics, vol.23, issue.4, pp.357-63, 2000.

G. Daltro, B. A. Franco, T. B. Faleiro, D. Rosário, P. B. Daltro et al., Osteonecrosis in sickle cell disease patients from Bahia, Brazil: a cross-sectional study, Int Orthop, vol.42, issue.7, pp.1527-1561, 2018.

A. Habibi, J. Arlet, K. Stankovic, J. Gellen-dautremer, J. Ribeil et al., Rev Med Interne, vol.36, issue.5, pp.5-8, 2015.

M. T. Gladwin, Cardiovascular complications and risk of death in sickle-cell disease, Lancet Lond Engl, vol.387, pp.2565-74, 2016.

, Haut Conseil de la Santé Publique, HCSP. Vaccinations des personnes immunodéprimées ou aspléniques. Recommandations [Internet, 2012.

L. Savale, B. Maitre, D. Bachir, F. Galactéros, G. Simonneau et al.,

, Presse Medicale Paris Fr, vol.42, issue.3, pp.338-384, 1983.

E. Hariri, A. Mansour, A. El-alam, Y. Daaboul, S. Korjian et al., Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment, Int Urol Nephrol, vol.50, issue.6, pp.1075-83, 2018.

M. Cazenave, B. Koehl, D. Nochy, P. Tharaux, and V. Audard,

, Nephrol Ther, vol.10, issue.1, pp.10-16, 2014.

A. Thrower, E. J. Ciccone, P. Maitra, V. K. Derebail, J. Cai et al., Effect of reninangiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease, Br J Haematol, vol.184, issue.2, pp.246-52, 2019.

M. Ndiaye, S. O. Niang, A. Diop, M. Diallo, K. Diaz et al.,

, Ann Dermatol Venereol, vol.143, issue.2, pp.103-110, 2016.

A. Alavi and R. S. Kirsner, Hemoglobinopathies and Leg Ulcers, Int J Low Extrem Wounds, vol.14, issue.3, pp.213-219, 2015.

, La consommation de tabac en France en 2014 : caractéristiques et évolutions récentes -Évolutions n°31 avec tableaux

S. C. Sadreameli, B. T. Kopp, S. E. Creary, M. N. Eakin, S. Mcgrath-morrow et al., Secondhand Smoke Is an Important Modifiable Risk Factor in Sickle Cell Disease: A Review of the Current Literature and Areas for Future Research, Int J Environ Res Public Health, vol.12, issue.11, 2016.

A. Benneh-akwasi-kuma, A. T. Owusu-ansah, M. A. Ampomah, F. Sey, E. Olayemi et al., Prevalence of relative systemic hypertension in adults with sickle cell disease in Ghana, PloS One, vol.13, issue.1, p.190347, 2018.

C. H. Pegelow, L. Colangelo, M. Steinberg, E. C. Wright, J. Smith et al., Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia, Am J Med, vol.102, issue.2, pp.171-178, 1997.

J. Zhou, J. Han, E. A. Nutescu, W. L. Galanter, S. M. Walton et al., Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis, Br J Haematol, 2019.

I. A. Yahaya, H. S. Isah, and P. O. Anaja, Serum fructosamine in the assessment of glycaemic status in patients with sickle cell anaemia, Niger Postgrad Med J, vol.13, issue.2, pp.95-103, 2006.

É. B. Mastandréa, F. Lucchesi, M. Kitayama, M. S. Figueiredo, and A. Citero-v-de, The relationship between genotype, psychiatric symptoms and quality of life in adult patients with sickle cell disease in São Paulo, Brazil: a cross-sectional study, Sao Paulo Med J Rev Paul Med, vol.133, issue.5, pp.421-428, 2015.

O. O. Seminog, O. I. Ogunlaja, D. Yeates, and M. J. Goldacre, Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study, J R Soc Med, vol.109, issue.8, pp.303-312, 2016.

P. Verger, L. Fressard, S. Cortaredona, D. Lévy-bruhl, P. Loulergue et al., Trends in seasonal influenza vaccine coverage of target groups in France, 2006/07 to 2015/16: Impact of recommendations and 2009 influenza A(H1N1) pandemic, Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull, issue.48, p.23, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02003912

Y. Zheng and R. W. Maitta, Alloimmunisation rates of sickle cell disease patients in the United States differ from those in other geographical regions, Transfus Med Oxf Engl, vol.26, issue.3, pp.225-255, 2016.

E. G. Da-cunha-gomes, L. Machado, .. F. De-oliveira, L. C. Neto, and J. , The erythrocyte alloimmunisation in patients with sickle cell anaemia: a systematic review, Transfus Med Oxf Engl, 2018.

D. Narbey, A. Habibi, P. Chadebech, A. Mekontso-dessap, M. Khellaf et al., Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease, Am J Hematol, vol.92, issue.12, pp.1340-1348, 2017.

S. Charache, M. L. Terrin, R. D. Moore, G. J. Dover, F. B. Barton et al., Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia, N Engl J Med, vol.332, issue.20, pp.1317-1339, 1995.

M. H. Steinberg, R. L. Nagel, and C. Brugnara, Cellular effects of hydroxyurea in Hb SC disease, Br J Haematol, vol.98, issue.4, pp.838-882, 1997.

A. M. Yates, L. Dedeken, M. P. Smeltzer, J. D. Lebensburger, W. C. Wang et al., Hydroxyurea treatment of children with hemoglobin SC disease. Pediatr Blood Cancer, vol.60, pp.323-328, 2013.

M. K. Miller, S. A. Zimmerman, W. H. Schultz, and R. E. Ware, Hydroxyurea therapy for pediatric patients with hemoglobin SC disease, J Pediatr Hematol Oncol, vol.23, issue.5, pp.306-314, 2001.

C. Summarell and V. A. Sheehan, Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease, Exp Biol Med Maywood NJ, vol.241, issue.7, pp.737-781, 2016.

L. Luchtman-jones, S. Pressel, L. Hilliard, R. C. Brown, M. G. Smith et al., Effects of hydroxyurea treatment for patients with hemoglobin SC disease, Am J Hematol, vol.91, issue.2, pp.238-280, 2016.

V. Naessens, R. Ward, and K. Kuo, A proposed treatment algorithm for adults with Haemoglobin SC disease, Br J Haematol, vol.182, issue.4, pp.607-616, 2018.

M. L. Mccaskill, O. Ogunsakin, T. Hottor, E. W. Harville, and R. Kruse-jarres, Serum 25-Hydroxyvitamin D and Diet Mediates Vaso-Occlusive Related Hospitalizations in SickleCell Disease Patients, Nutrients, vol.10, issue.10, 2018.

, Maladies auto-immunes

, Inserm -La science pour la santé, 2019.

, Glucose-6-Phosphate Deshydrogenase) ou FAVISME, 2019.

G. J. Kato, M. T. Gladwin, and M. H. Steinberg, Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes, Blood Rev, vol.21, issue.1, pp.37-47, 2007.

S. Maurel, S. Stojanovic, K. Avellino, V. Girshovich, A. Letavernier et al., Prevalence and correlates of metabolic acidosis among patients with homozygous sickle cell disease, Clin J Am Soc Nephrol CJASN, vol.9, issue.4, pp.648-53, 2014.

S. Charache, G. J. Dover, R. D. Moore, S. Eckert, S. K. Ballas et al., Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia

, Blood, vol.79, issue.10, pp.2555-65, 1992.

M. S. Thein, N. E. Igbineweka, and S. L. Thein, Sickle cell disease in the older adult. Pathology (Phila), vol.49, pp.1-9, 2017.

A. Afenyi-annan, M. Kail, M. R. Combs, E. P. Orringer, A. Ashley-koch et al., Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion (Paris), vol.48, pp.917-941, 2008.

E. M. Do-nascimento, C. L. De-castro-lobo, B. De-bragança-pereira, and S. K. Ballas, Survival Probability in Patients with Sickle Cell Anemia Using the Competitive Risk Statistical Model, Mediterr J Hematol Infect Dis, vol.11, issue.1, p.2019022, 2019.

. Tweel-xw-van-den, J. H. Lee, . Van-der, H. Heijboer, M. Peters et al., Development and validation of a pediatric severity index for sickle cell patients, Am J Hematol, vol.85, issue.10, pp.746-51, 2010.